Engineering Technologies and Clinical Translation: Volume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy

Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy explores the challenges of delivering immuno-oncology therapies and developing solutions for drug delivery and clinical outcomes. It discusses biomaterial, microfluidic, and biodegradable devices, engineered microbes, personalized medicine, and clinical approval processes.

Format: Paperback / softback
Length: 524 pages
Publication date: 27 August 2021
Publisher: Elsevier Science & Technology

Immuno-oncology (IO) is a rapidly evolving field at the intersection of immunology and cancer biology, resulting in the development of innovative therapeutic approaches like chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, which have been clinically approved for the treatment of cancer. While currently approved IO approaches have demonstrated significant promise in treating certain types of cancer, the broader application of IO strategies has the potential to enhance clinical success, particularly in diseases such as pancreatic cancer and brain tumors, where IO has had limited efficacy thus far.

This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy explores a wide range of IO technologies, including biomaterials, microfluidics, biodegradable devices, engineered microbes, personalized medicine, clinical approval processes, and many others. By bringing together experts from the fields of immunology, cancer biology, and therapeutics, this treaty provides a comprehensive exploration of potential solutions from the nanotechnology and drug delivery perspectives.

The challenges of delivering immuno-oncology therapies are extensively examined in this volume, with a particular focus on the development of solutions for drug delivery and their clinical outcomes. The authors discuss the importance of designing effective drug delivery systems that can target cancer cells while minimizing systemic toxicity. They also explore the use of nanotechnology and drug delivery platforms, such as nanoparticles, liposomes, and gene therapy vectors, to enhance the efficacy and safety of immuno-oncology therapies.

In addition to drug delivery, the volume also addresses the clinical outcomes of immuno-oncology therapies. The authors discuss the importance of monitoring patients for side effects and developing strategies to manage them effectively. They also explore the role of personalized medicine in tailoring immuno-oncology therapies to individual patients' genetic profiles and tumor characteristics.

The authors of this volume draw on their extensive expertise and research to provide readers with a comprehensive understanding of the challenges and opportunities in delivering immuno-oncology therapies. The treaty is well-organized and accessible, making it an invaluable resource for researchers, clinicians, and policymakers involved in the field of cancer immunotherapy.

In conclusion, Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy is a groundbreaking treaty that provides a comprehensive exploration of the challenges and opportunities in delivering immuno-oncology therapies. By bringing together experts from diverse fields, the volume offers potential solutions from the nanotechnology and drug delivery perspectives, ultimately improving the clinical success of immuno-oncology therapies for patients with cancer.

Weight: 450g
Dimension: 235 x 191 (mm)
ISBN-13: 9780323909495